info@ttramyloidosis.uk
UK ATTR Amyloidosis Patients Association
  • Home
  • ATTR Amyloidosis
    • Introduction
    • Hereditary
    • Wild type
  • Diagnosis and Treatment
    • Introduction
    • Diagnosis
    • Drug Treatment
    • Supportive Treatment for Heart Disease
    • Supportive Treatment for Neuropathy
  • Patient Resources
    • Leaflets and newsletters
    • FAQ
    • NAC Patient website
    • Support forum
    • Support groups
    • International Conferences
    • Pharma
    • International patient groups
  • Research
  • FAQ
  • News
  • Privacy Policy

UK ATTR Amyloidosis Patients Association

About Us

The UK ATTR Amyloidosis Patients’ Association (UKATPA) was founded in 2017 by a group of UK patients with transthyretin (TTR)-type systemic amyloidosis (ATTR), supported by the consultant physicians of the UK NHS National Amyloidosis Centre. In recent years there have been major advances in the field of ATTR amyloidosis....

Learn More

ATTR Amyloidosis

Amyloidosis Amyloidosis is a rare disease caused by abnormal deposition and accumulation of proteins in the tissues of the body. Amyloid deposits are primarily made up of protein fibres known as amyloid fibrils. These amyloid fibrils are formed… Read More

Learn More

Diagnosis and Treatment

All patients with suspected or diagnosed ATTR amyloidosis should be assessed in a dedicated specialist unit. In the UK, the referral centre is the NHS National Amyloidosis Centre (NAC) at the Royal Free Hospital, London. Information for referring physicians in… Read More

Learn More

Patient Resources

Information about the UK ATTR Amyloidosis Patients Association (UKAPTA) The UK National Amyloidosis Centre Amyloidosis Awareness Programme has provided extensive patient information and support since 2013. Resources of interest to patients with ATTR amyloidosis include: NAC resources: Information… Read More

Learn More

Research

New drugs for ATTR amyloidosis

In recent years effective new drugs for ATTR amyloidosis have become available. These drugs can improve symptoms and delay disease progression in suitable patients. Several other drugs are in various stages of development, offering yet more hope for the future. The trials discussed below are ongoing at the London National Amyloidosis Centre. For more details on each trial, see clinicaltrials.gov

Read More

Copyright © 2021 · All Rights Reserved · UK ATTR Amyloidosis Patients Association

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Reject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT